Semaglutide vs Tirzepatide

A detailed side-by-side comparison of Semaglutide and Tirzepatide covering dosing, storage, research findings, and practical usage.

Overview

Semaglutide: A GLP-1 receptor agonist used for weight management and blood sugar control.

Tirzepatide: A dual GIP and GLP-1 receptor agonist for weight management.

Comparison Table

Semaglutide Research

Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for Type 2 diabetes (Ozempic) and later approved for chronic weight management (Wegovy). It mimics the hormone GLP-1, which regulates appetite, food intake, and blood sugar levels. Clinical trials have demonstrated impressive weight loss results, with participants losing an average of 15-17% of body weight over 68 weeks. Semaglutide works by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. It also shows cardiovascular benefits, reducing major adverse cardiac events in at-risk patients. The once-weekly dosing makes it convenient compared to daily alternatives.

Tirzepatide Research

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist FDA-approved for Type 2 diabetes (Mounjaro) and weight management (Zepbound). Unlike semaglutide which only targets GLP-1, tirzepatide activates both GIP and GLP-1 receptors, providing enhanced metabolic benefits. Clinical trials (SURMOUNT) showed unprecedented weight loss results, with participants losing up to 22.5% of body weight - more than any other approved medication. It improves insulin sensitivity, reduces appetite, and may have additional benefits for fatty liver disease. The dual mechanism appears to provide superior efficacy compared to GLP-1 agonists alone.

Semaglutide Full Guide | Tirzepatide Full Guide | Dosage Calculator | Shop Peptides

For laboratory research use only. Not for human consumption.